Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1542 Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for Neuroendocrine Tumors?

Introduction: Neuroendocrine tumors are heterogeneous, often functional malignancies and their therapeutic options are limited. As the PI3 kinase signaling is ­in GEP-NENs, selective PI3Kalpha inhibitors may be more potent than panPI3K inhibitors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Grabowski P

Authors: Nölting S, Rentsch J, Freitag H, Briest F, Schrader J,

Keywords: PI3Kalpha, BYL719, neuroendocrine tumor cell lines,

#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro

Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Briest F

Authors: Briest F, Christen F, Worpenberg L, Welzel M, Freitag H,

Keywords: GEP-NEN, targeted therapy, DNA repair, chemotherapy,

#1172 Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The “crosstalk” of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Freitag H, Briest F, Christen F, Grass I, Lewens F,

Keywords: dual inhibition, PI3K, mTOR, PKI-587,RAD001, signaling,

#1003 Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block

Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lewens F

Authors: Lewens F, Freitag H, Briest F, Heilmann M, Schneider C,

Keywords: bronchial, NETs, PI3K, FoxM1, survivin, cell lines, SCLC,

#1001 Forkheadbox Proteins as Novel Drug Targets in Gastroenteropancreatic Neuroendocrine Tumor Disease: Inhibition of FoxM1 Exerts Antiproliferative Effects in GEP-NEN Cell Lines

Introduction: Forkheadbox proteins (Fox proteins) are transcriptions factors. They are highly conserved key players in a large number of cellular processes. Fox proteins have been described as acting as both tumor suppressors and oncogenes. Most notably, they operate in the context of the majority of cancer-related pathways. Information about the fuunction of these proteins in gastroenteropancreatic neuroendocrine neoplasias is scant.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Briest F

Authors: Briest F, Freitag H, Lewens F, Kaemmerer D, Hörsch D,

Keywords: Forkheadbox proteins, signalling network, immunohistochemistry, siRNA, microarray technique,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.